Morishige, Kazuhisa et al. published their research in Experimental Parasitology in 1995 | CAS: 13146-72-0

9-((2R,3R,5S)-3-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol (cas: 13146-72-0) belongs to tetrahydrofuran derivatives.Tetrahydrofuran has many industry uses as a solvent including in natural and synthetic resins, high polymers, fat oils, rubber, polymer. Tetrahydrofuran can also be produced, or synthesised, via catalytic hydrogenation of furan. This process involves converting certain sugars into THF by digesting to furfural. An alternative to this method is the catalytic hydrogenation of furan with a nickel catalyst.COA of Formula: C10H12N4O4 

Leishmania donovani: pilot study for evaluation of therapeutic effects of inosine analogs against amastigotes in vitro and in vivo was written by Morishige, Kazuhisa; Aji, Toshiki; Ishii, Akira; Yasuda, Tatsuji; Wataya, Yusuke. And the article was included in Experimental Parasitology on June 30,1995.COA of Formula: C10H12N4O4  The following contents are mentioned in the article:

The inhibition by carbocyclic inosine (C-Ino), 3′-deoxyinosine (3′-dI), and 3′-deoxy-3′-fluoroinosine (3′-FI) of Leishmania donovani amastigotes was examined J774.1 cells (a mouse macrophage line) were cultured in GIT medium with lipopolysaccharide and hemin and infected with the parasite. C-Ino (3 μM) completely inhibited and 3′-dI (30 μM) reduced to 40% the infection rate on Day 6 after infection. The standard pentostam (30 μM) resulted in a 38% infection rate. The therapeutic efficacies of nonentrapped free and liposome-entrapped inosine analogs were tested in mice infected with L. donovani. The mice were injected i.v. five times on alternate days, beginning 2 days after infection. Treatment with the nonentrapped free inosine analog of C-Ino (100 mg/kg), 3′-dI (100 mg/kg), or 3′-FI (50 mg/kg) resulted in an LDU (Leishmania donovan units) that were 94, 68, or 73% lower, resp., than the control values. Treatment with the corresponding entrapped inosine analog (10 mg/kg) caused decreases of 90, 69, or 68% LDU, resp. The entrapped inosine analogs were inhibitory at doses one-fifth to one-tenth of the nonentrapped free inosine analogs. C-Ino had the strongest inhibitory effect among the three analogs tested in vitro and in vivo. Liposome-entrapped C-Ino had no severe side effects, although spleen weight increased. The agent may be useful as an antileishmanial drug. This study involved multiple reactions and reactants, such as 9-((2R,3R,5S)-3-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol (cas: 13146-72-0COA of Formula: C10H12N4O4 ).

9-((2R,3R,5S)-3-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol (cas: 13146-72-0) belongs to tetrahydrofuran derivatives.Tetrahydrofuran has many industry uses as a solvent including in natural and synthetic resins, high polymers, fat oils, rubber, polymer. Tetrahydrofuran can also be produced, or synthesised, via catalytic hydrogenation of furan. This process involves converting certain sugars into THF by digesting to furfural. An alternative to this method is the catalytic hydrogenation of furan with a nickel catalyst.COA of Formula: C10H12N4O4 

13146-72-0;9-((2R,3R,5S)-3-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol;The future of 13146-72-0;New trend of C10H12N4O4 ;function of 13146-72-0